Pubblicazioni scientifiche

HIRSCH (H) INDEX : 36 (DATI SCOPUS 2022)

CITAZIONI TOTALI: 6625 (DATI SCOPUS 2022)

CITAZIONI MEDIE PER PUBBLICAZIONE : 2.4 (DATI SCOPUS 2022)

IMPACT FACTOR TOTALE 749.1(SU 161 PUBBLICAZIONI)

IMPACT FACTOR MEDIO. 4,6

 

 

L’attività scientifica continuata senza interruzioni dal 1990 ad oggi, comprende  298 pubblicazioni in estenso 

 

Per la complessità delle metodiche impiegate, le pubblicazioni sono spesso in collaborazione, ma tra i collaboratori la sua attività e il suo apporto individuale appaiono sempre preminenti e ben individuabili .

L’ attività scientifica si è articolata complessivamente sulla maggior parte degli aspetti del settore scientifico urologico, con ricerche di base e cliniche ad alto  livello di originalita’ ed innovativita’. Tuttavia una particolare attenzione è stata rivolta ai seguenti argomenti:

-ipertrofia prostatica benigna: ricerca di base, ricerca clinica, ricerca chirurgica

-carcinoma prostatico: ricerca di base, ricerca clinica, ricerca chirurgica

-carcinoma renale: ricerca clinica, ricerca chirurgica

 

Le ricerche sono state eseguite in collaborazione multidisciplinare con gruppi di ricerca particolarmente con :

  • Dipartimento Medicina Sperimentale, Universita’ Sapienza
  • Fisiopatologia Medica- Endocrinologia, Universita’ Sapienza
  • Dipartimento Malattie Infettive, Universita’ Sapienza
  • Istituto Superiore di Sanita’, Roma
  • Istituto Anatomia Patologica e Patologia Generale, Universita’ Sapienza
  • Istituto Radiologia, Universita’ Sapienza
  • Universita’ La Sapienza di Roma
  • Ospedale S. Andrea di Roma
  • Universita’ di Njimegen (Belgio)
  • Memorial Sloan Catering (New York)
  • University of Sourth California

Elenco complessivo delle pubblicazioni scientifiche

1. Lubrano C, Sciarra A, Armellini S, Flammia GP, Wongher L, Caponera M.
Legame del fattore di crescita epidermico e contenuto dei recettori steroidei nella ipertrofia prostatica benigna umana.
Estratto da: Premio Rodolfo Ferrari SIU.Ed. Panante, Firenze 1990,53-63.

2. Di Silverio F, D’Eramo G, Flammia GP, Sciarra A, Lubrano C, Petrangeli E, Sciarra F.
Fattori di crescita nell’ipetrofia prostatica benigna.
Acta Urol.Ital. 4,233- 238,1991.

3. Di Silverio F, D’Eramo G, Caponera M, Persechino F, Sciarra A, Oke E.
Il carcinoma prostatico incidentale: quattro anni di follow up dopo terapia con ciproterone acetato.
Acta Urol.Ital. 5,303-306,1991.

4. Di Silverio F, D’Eramo G, Flammia GP, Sciarra A, Oke E, Macri’ D, Caponera M.
Physiopatology of prostatic function.
Estratto da: Update on therapy in andrology; II International Congress on Therapy in Andrology.G.F.Menchini Fabris,D.Canale eds. Pisa giugno 1991,169-179.

5. Di Silverio F, Sciarra A, D’Eramo G, Tenaglia R.
Trattamento non chirurgico dell’ipertrofia prostatica benigna.
Estratto da: Patologie Prostatiche. Atti II Corso Internazionale di Urologia Oncologica.
Acta Medica Eds. Chieti nov. 1991,1, 29-37.

6. Di Silverio F, D’Eramo G, Flammia GP, Caponera M, Macri’ D, Loreto A, Sciarra A.
New  Ultrasensitive   assay  development   by  using  monoclonal  antibodies for detecting prostate specific antigen.
Eur.Urol. 21,suppl.1,79-82,1992.

7. Flammia GP, D’Eramo G, Caponera M, Macri’ D, Sciarra A, Oke E, Di Silverio F.
Correlazione tra grado, ploidia cellulare e sopravvivenza nei pazienti con carcinoma renale in stadio I secondo Robson.
Acta Urol.Ital. VI,suppl.4 71-72,1992.

8. D’Eramo G, Flammia GP, Caponera M, Sciarra A, Macri’ D, Loreto A, Di Silverio F.
Evoluzione delle metodiche radiologiche nella diagnosi del carcinoma renale incidentale (1975-1991).
Acta Urol.Ital. VI,suppl.4 77-78,1992.

9. D’Eramo G, Caponera M, Flammia GP, Sciarra A, Oke E, Frascaro E, Di Silverio F.
Valore prognostico delle variazioni dei diametri prostatici in pazienti con carcinoma prostatico in terapia ormonosoppressiva.
Acta Urol.Ital. VI,suppl.4 169-170,1992.

10. Caponera M, D’Eramo G, Flammia GP, Sciarra A, Frascaro F, Macri’ D, Di Silverio. F
Attivita’ antiestrogenica della Serenoa Repens B in tessuto prostatico di pazienti con ipertrofia prostatica benigna.
Acta Urol.Ital. VI,suppl.4 271-272,1992.

11. Lubrano C, Sciarra A, Armellini S, Flammia GP, Wongher L, Caponera M.
Legame del fattore di crescita epidermico e contenuto  dei recettori steroidei nella ipertrofia prostatica benigna.
Min.Urol.Nephrol. 44 (1),9-14,1992.

12. Di Silverio F, D’Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, Caponera M, Sciarra F.
Evidence  that  serenoa  repens  extract  displays  an  antiestrogenic  activity in prostatic tissue of benign prostatic hypertrophy patients.
Eur. Urol.21 ,309-314, 1992.

13. Di Silverio F, D’Eramo G, Caponera M, Macri’ D, Sciarra A, Buscarini M.
PSA as a prognostic factor in prostate cancer.
Estratti da: Prognostic factors in urological cancers,Breul J. and Hartung R (eds.).1st Internat. Symposium. Munchen (Germania) 1992,45-54.

14. Di Silverio F, D’Eramo G, Flammia GP, Caponera M, Sciarra A, Concolino G.
Il carcinoma del rene come tumore ormonodipendente.
Estratto da: I tumori urologici, recenti progressi e nuovi obbiettivi della ricerca. Societa’ Italiana di Prevenzione Diagnosi e Terapia dei Tumori SIPDTT Bologna,Monduzzi Edt.,nov. 1992,1,207- 21.

15. Di Silverio F. (aknowledgements Sciarra A.)
Use of terazosine in the medical treatment of benign prostatic hyperplasia:experience in Italy.
Br.J.Urol. 70 suppl.1,22-25,1992.

16. Di Silverio F, Flammia GP, Sciarra A, Buscarini M, Mauro M, Mariani M, Frascaro E.
Ipertrofia prostatica benigna.
Estratti da:Terapia medica in urologia.F.Di Silverio;Marrapese edt.,Roma 1992,39- 48.

17. Di Silverio F, D’Eramo G, Flammia GP, Caponera M, Frascaro E, Buscarini M, Mariani M, Sciarra A.
Pathology of BPH.
Min. Urol. Nephrol,45,4,135-142,1993.

18. Di Silverio F, Flammia GP, Sciarra A, Caponera M, Mauro M, Buscarini M, Tavani M, D’Eramo G.
Plant extracts in BPH.
Min. Urol. Nephrol,45,4,143-9,1993.

19. Di Silverio F, D’Eramo G, Caponera M, Flammia GP, Izzi R, Sciarra A, Macri’ D, Buscarini M.
The role of hormonal therapy in the treatment of prostate carcinoma.
Rays 18,1,94-114,1993.

20. Di Silverio F, D’Eramo G, Flammia GP, Frascaro E, Buscarini M, Mariani M, Sciarra A.
Association pharmacologiques dans treatment de l’hypertropie prostatique benigne.
Journal d’Urologie vol.99,6,316-320,1993.

21. Di Silverio F, D’Eramo G, Flammia GP, Buscarini M, Loreto A, Di Chiro C, Sciarra A.
Ipertrofia prostatica benigna: terapia attuale.
Federazione medica 14,7- 13, nov.1993.

22. Di Silverio F, D’Eramo G, Flammia GP, Buscarini M, Sciarra A.
Pharmacological treatment of benign prostatic hypertrophy :plant extracts.
Estratto da: Contemporary BPH management. P.Puppo;Monduzzi edt. 1993 Bologna,43-52.

23. Di Silverio F, Flammia GP, Sciarra A.
Le patologie prostatiche benigne.
Estratto da:Medicina clinica diagnostica e terapia. Edizioni Medico Scientifiche Torino.Aggiornamento sept.1993,vol.III 293-319.

24. Di Silverio F, D’Eramo G, Flammia GP, Sciarra A, Buscarini M, Mauro M, Sciarra F.
Cost effectiveness in the management of Benign Prostatic  Hyperplasia:Italian  data.
Min.Urol. Nephrol,46,2,93-99,1994.

25. Di Silverio F, D’Eramo G, Buscarini M, Sciarra A, Casale P, Loreto A, Di Nicola S, Seccareccia F.
Influence of DNA ploidy, PSA levels and Gleason sum in disease free survival after radical surgery for prostatic cancer.
Estratto da: 2nd Euro-American conferences on Urological diseases,BPH and prostate cancer. Agosto 1994, Athenes (Grecia),137-145.

26. Di Silverio F, D’Eramo G, Buscarini M, Flammia GP, Sciarra A, Gallucci M.
Prostatectomia radicale.
Estratto da: Atti congresso V Giornata  Chirurgica,  Orbetello  aprile  1994,295-  299.

27. Di Silverio F, D’Eramo G, Sciarra A, Casale P, Di Nicola S, Frascaro E, Buscarini M, Loreto A, Di Chiro C, Colella D.
Approccio farmacologico all’ipertrofia prostatica benigna:r azionale dell’utilizzo degli alfa1 bloccanti nell’esperienza clinica.
Estratto da: Aggiornamento sul ruolo degli alfa1 bloccanti: farmacologia e clinica. Ed.Mediprint Roma, dic.1994,1,19-26.

28. Di Silverio F, D’Eramo G, Flammia GP, Buscarini M, Sciarra A, Casale P, Loreto A, Frascaro E, Di Chiro C.
The  use of   alpha   adrenergic   blockers   in patients  with Benign Prostatic Hyperplasia.
Estratto da: Int.Ass. Gerontol.. European Legion Clinical Section congress. Firenze,June 16-19,1994. Geriatrics (ed. M.Passeri),57-66,1994.

29. D’Eramo G, Sciarra A, Mariani M, De Marco F, Caponera M, Flammia GP, Tavani M, Buscarini M, Di Palma P, Di Silverio F.
Correlazione fra cisti renali semplici ed ipertensione arteriosa: valutazione di 92 casi.
Estratto da: Urologia oggi SUICMI, Atti 41° convegno Urologia dell’Italia Centro Meridionale e delle Isole, Chieti ottobre 1992,79-84, 1994.

30. D’Eramo G, Caponera M, Mariani M, Flammia GP, Sciarra A, Macri’ D, Buscarini M, Loreto A, Di Palma P, Di Silverio F.
Un caso di carcinoma muciparo della prostata: problemi terapeutici e valutazione del follow-up.
Estratto da: Urologia oggi SUICMI, Atti 41° convegno Urologia dell’Italia Centro Meridionale e delle Isole, Chieti ottobre 1992,275-277, 1994.

31. De Matteis A, D’Eramo G, Caponera M, Flammia GP, Sciarra A, Macri’ D, Tavani M, Buscarini M, Di Silverio F.
Il citoaspirato e la biopsia istologica nella diagnosi del carcinoma prostatico.
Estratto da: Urologia SUICMI Atti 41° convegno Urologia dell’Italia Centro Meridionale e delle Isole, Chieti ottobre 1992,207- 210,1994.

32. D’Eramo G, Flammia GP, Sciarra A, Mariani M, Macri’ M, Caponera M, Buscarini M, Loreto A, Di Palma P, Di Silverio F.
Metastasi orbitaria da carcinoma prostatico: valutazione della risposta alla terapia ormonosoppressiva
Estratto da: Urologia SUICMI Atti 41° convegno Urologia dell’Italia Centro Meridionale e delle Isole, Chieti ottobre 1992,279-80, 1994.

33. Flammia GP, D’Eramo G, Mariani M, Caponera M, De Marco F, Ombres M, Sciarra A, Loreto A, Di Palma P, Di Silverio F.
Su due casi di osteosarcoma renale  terapia e follow-up.
Estratto da: Urologia SUICMI Atti 41° convegno Urologia dell’Italia Centro Meridionale e delle Isole, Chieti ottobre 1992,293-296, 1994.

34. Di Silverio F, D’Eramo G, Buscarini M, Sciarra A, Casale P, Loreto A, Di Nicola S, Frascaro E.
Dipping ultrasonography (DUS): a new method of assessing margin of resection during radical retropubic prostatectomy.
Estratto da: 2nd Euro-American conferences on Urological diseases,BPH and prostate cancer. Agosto 1994, Athenes (Grecia),127-136.

35. Di Silverio F, D’Eramo G, Buscarini M, Sciarra A, Di Nicola S, Casale P, Loreto A, De Marco F, Seccareccia F.
New developments in diagnosis : does ultrasensitive PSA Assay have any advantages?
Proceedings 4th International Symposium on Recent Advances in Urological Cancers. Diagnosis and Treatment. Paris, June 1994 ; eds. G. Murphy-S Khoury ; 88-92

36. Di Silverio F, D’Eramo G, Caponera M, Flammia GP, Casale P, Di Nicola S, Buscarini M, Colella D, Sciarra A.
Ipertrofia prostatica benigna.
Agg. Medico (Kurtis Milano eds)19,2,39-58,marzo 1995.

37. D’Eramo G, Buscarini M, Sciarra A, Casale P, Di Nicola S, Loreto A, Colella D, Di Chiro C, Diana M, Di Silverio F.
Importanza dei criteri di selezione nei pazienti sottoposti a terapia ormonale neoadiuvante e prostatectomia radicale per carcinoma prostatico.
Urologia vol.62,1,51-55, 1995.

38. Di Silverio F, D’Eramo G, Buscarini M, Casale P, Di Nicola S, Colella D, Sciarra A.
Is there always a role for radical prostatectomy in the treatment of localized prostate cancer?
Min.Urol.Nefrol.,47;117-24,1995.

39. Di Silverio F, D’Eramo G, Sciarra A, Buscarini M, Casale P, Di Nicola S, Colella D.
Growth factors in benign prostatic hyperplasia and prostate cancer.
Urologia 62,4,509-517, 1995.

40. Di Silverio F, Sciarra A, Colella D.
La randomizzazione e i problemi etici : stato dell’arte.
Estratto da: Urologia Oggi SUICMI Atti 44° Convegno Societa’ Urologia dell’Italia Centro Meridionale e delle Isole.S.Felice Circeo sett. ’95 suppl. vol.4,33-36,1995.

41. Di Silverio F, Sciarra A, Di Nicola S, Casale P, Buscarini M, Di Chiro C, D’Eramo G.
Is medical therapy an expensive way for delaying surgery in BPH patients?
Min.Urol.,47,4,177-184, 1995.

42. Di Silverio F, Sciarra A, D’Eramo G, Di Nicola S, Buscarini M, Casale P, Colella D, Di Chiro C, Paoluzzi M.
Influenza degli isoflavonidi ed altri componenti della dieta alimentare nello  sviluppo del carcinoma prostatico.
Estratto da: XII Appuntamento oncologico ospedaliero ,Prospettive in endocrinoterapia oncologica. Annali dell’Istituto Carlo Forlanini. vol. XV suppl. 1 Roma,18 dic.1995,59-60.

43. Di Silverio F, Sciarra A, D’Eramo G, Di Nicola S, Colella D, Paoluzzi M.
Gli LHRH agonisti nella oncologia urologica: stato dell’arte.
Estratto da: XII Appuntamento oncologico ospedaliero ,Prospettive in endocrinoterapia oncologica.
Annali dell’Istituto Carlo Forlanini.vol. XV suppl. 1 Roma,18 dic.1995,37-39.

44. Di Silverio F, D’Eramo G, Sciarra A, Buscarini M, Casale P, Di Nicola S, Colella D.
Is there always a role for radical prostatectomy in the treatment of localized prostate cancer?
Estratto da: Bullettin of the Mediterranean Urological Association. 4th Congress of Rhodes,Grecia,sett.1995,6-7.

45. Di Silverio F, Sciarra A, Di Chiro C, Von Heland M.
Dieta e tumori urologici.
Estratto da: 1° Convegno Oncologico Nazionale. S.Maria Imbaro, ott. 1995,3-6.

46. Sciarra A, Casale P.
Evoluzione della ricerca sull’ipertrofia prostatica benigna: storia naturale ed eziopatogenesi.
Estratto da: Ipertrofia prostatica benigna .F. Di Silverio e M. Caponera; Verduci editore, Roma 1995,27-49.

47. Di Nicola S, Giulianelli R, Sciarra A, Casale P, Di Chiro C.
Prostatectomia radicale retropubica nerve-sparing: valutazione della sopravvivenza libera da malattia e della funzione erettile.
Atti Congresso Chirurgia Polispecialistica: 1à giornate di studio. Edt. A. Trecca. Roma, 1995, 43-45.

48. Di Silverio F, D’Eramo G, Buscarini M, Sciarra A, Di Nicola S, Casale P, Loreto A, Colella D.
Carcinoma prostatico in fase avanzata: problemi terapeutici e di follow-up.
Atti: Carcinoma della Prostata :Stato dell’arte; Roma 1995 Edt. G.Fischetti.12-15.

49. Di Silverio F, D’Eramo G, Buscarini M, Sciarra A, Casale P, Loreto A, Di Nicola S, Seccareccia F, De Vita R.
DNA ploidy,Gleason score,Pathologic stage and serum PSA levels as predictors of disease free survival in C-D1 prostate cancer patients submitted to radical retropubic prostatectomy.
Eur. Urol. 30,3,316-321,1996.

50. Di Silverio F, D’Eramo G, Buscarini M, Sciarra A, Casale P, Di Nicola S, Loreto A, Colella D.
Role of prostate specific antigen in the stage,grade  and  nuclear  ploidy  in  patients with locally advanced prostatic carcinoma.
Evaluation of 57 cases with follow up of 23-82 months(average 45 months). Acta Urol. Ital. 10,2;151-154;1996.

51. Di Silverio F, Sciarra A, D’Eramo G, Casale P, Di Nicola S, Buscarini M, Di Chiro C, Loreto A.
Patients with benign prostatic hyperplasia (BPH):medical therapy or surgery ? Estratto  da:  BPH,from  molecular  biology  to  patient  relief. 
Proceedings of the conference held in the 4th Mediterranean Congress of Urology.  Dimopoulos C.A. and Di Silverio F. (eds.) Bologna,89-96,1996.

52. Di Silverio F, Sciarra A.
Fattori di crescita: strategie cliniche e terapeutiche.
Estratto da: Ricerca di base in Urologia,F.Di Silverio ed. Atti 1° Congr. Nazionale Ass. Ricerca di Base in Urologia, S.Felice Circeo sett.1995 . 1;43-52, 1996.

53. Di Silverio F, D’Eramo G, Flammia GP, Buscarini M, Casale P, Di Nicola S, Sciarra A.
Effets compares de l’incision cervico-prostatique (ICP) et de l’association ICP et agonistes de la LHRH dans le traitment de l’hypertrophie benigne de la prostate.
Journal d’Urologie 102,3,111-116,1996.

54. Di Silverio F, Sciarra A, Flammia GP, Mariani M, De Vico A, Buscarini M.
Surgical enucleation for renal cell carcinoma (RCC) Prognostic significance of tumor stage, grade and DNA ploidy.
Scand J urol 31: 123-28;1996

55. Sciarra A, Di Silverio F.
Safety profile of selective alpha 1 adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
Min.Urol.49,21-8, 1997.

56. Di Silverio F, Sciarra A, Di Nicola S, Di Chiro C.
Peptide growth factors: clinical and therapeutic strategies.
Min.Urol. 49,63-72,1997

57. Di Silverio F, Sciarra A, Flammia GP, Mariani M, De Vico A.
Multiple primari tumors: 17 cases of renal cell carcinoma associated with primary tumors involving different hormone target tissue.
World J Urol 15;203-209;1997

58. Sciarra A, Casale P, Di Chiro C, Di Nicola S, Di Silverio F.
New aspects on prostate cancer:hereditary form,developmental estrogenization and differentiation therapy.
Min.Urol. Nefrol. 1998;50:185-90

59. Di Silverio F, D’Eramo G, Buscarini M, Sciarra A, Di Nicola S, Casale P.
Ruolo dell’antigene specifico prostatico e dei suoi derivati nella diagnosi del carcinoma prostatico.
Min.Urol.Nefrol. 1998;50:143-154.

60. Sciarra A, D’Eramo G, Casale P, Di Nicola S, Loreto A, Buscarini M, Di Silverio F.
Relationship among symptom score, prostate volume and urinary flow rate in 543 men with and without benign prostatic hyperplasia.
The Prostate 1998;34:121-128
IF 3.2

61. Di Silverio F, Sciarra A, Casale P, Di Chiro C, Buscarini M, D’Eramo G.
L’immagine e l’anatomia patologica:il significato dell’atrofia ghiandolare focale nei pazienti con carcinoma prostatico.
Atti ARBU Roma 1998; edt F Di Silverio:49-57.

62. Di Silverio F, Sciarra A, D’Eramo G, Casale P, Loreto A, Seccareccia F.
Relationship among age,prostate specific antigen and prostate volume in men with LUTS and in different groups of men with and without benign and  malignant prostate diseases.
The Prostate 1998;36:1-8
IF 3.2

63. Di Silverio F, Monti S, Martini C, Lanzana S, D’Eramo G, Di Nicola S, Sciarra A, Toscano V.
Effects of long term treatment with serenoa repens on the concentrations and regional distribution of androgen and epidermal growth factor in benign prostatic hyperplasia.
The Prostate 1998;37:77-83.
IF 3.2

64. Sciarra A, Casale P, Di Chiro C, Di Nicola S, Di Silverio F.
Hormonal profile of patients with Leydif cell tumors:a urologic cause of gynecomastia.
Min.Urol.Nefrol. 1998;50:241-6

65. Di Silverio F, Sciarra A, Casale P, Seccareccia F.
Can the intraprostatic concentration of epidermal growth factor influence the variance of serum prostate specific antigen levels in patients with benign prostatic hyperplasia?
J Urol. 1999;161(1):128-32.
IF 2.5

66. Sciarra A, Casale P, Di Nicola S, Di Chiro C, Coltella D, Di Silverio F.
Limiti nella interpretazione dei livelli sierici dell’antigene specifico prostatico.
Min.Urol.Nefrol 1999;51:105-12.

67. Di Silverio F, D’Eramo G, Casale P, Di Nicola S, Coltella C, Di Chiro C, Sciarra A.
Molecular biology in prostate carcinoma.
Acta Urol Nefrol 1999;13(2):97-101

68. Sciarra A, Casale P, Coltella D, Di Chiro C, Di Silverio F.
Hormone-refractory prostate cancer? Antiandrogen withdrawal and intermittent hormone therapy.
Scand J Urol 1999;33:211-6.(Review Article)

69. Sciarra A, D’Eramo G, Di Nicola S, Di Chiro C, Di Silverio F.
Penile metastases from carcinoma of the prostate in a patient with high serum prostate specific antigen levels.
Min.Urol.Nefrol. 1999;51:157-8

70. Gallucci M, Alcini A, Sciarra A.
L’ipertrofia prostatica benigna.
Min.Urol.Nefrol. 1999; 51(suppl1 al N.3):13-6

71. Di Silverio F, Casale P, Colella D, Loreto A, Seccareccia F, Sciarra A.
Independent value of tumor size and DNA ploidy for the prediction of disease Progression in patients with organ confined Renal Cell Carcinoma.
Cancer 2000;88(4):835-45.
IF 3.2

72. Sciarra A, Di Chiro C, Voria G, Coltella D, Loreto A, Pastore A, Di Silverio F.
Intermittent androgen deprivation in patients with localized prostate cancer and a Biochemical progression after radical prostatectomy
Min Urol Nefrol 2000;52(1):1-7

73. Sciarra A, Di Chiro C, Di Silverio F.
Intermittent androgen deprivation in patients with biochemical failure after radical Prostatectomy for clinically localized prostate cancer:the role of Gleason score.
World J Urol 2000;18(6):392-400. IF 1.3

74. Sciarra A, Voria G, Pastore A, Loreto A, Di Chiro C, Gentile V, Di Silverio F.
Role of nitric oxide in different organs of the genitourinary system: physiology and pathology.
Min Urol Nefrol 2000;52(4):201-6

75. Sciarra A, Pastore AL, Cardi A, Voria G, Di Silverio F.
Hereditary neoplasm in urology.
Min Urol 2001; 53(3):171-7

76. Gentile V, Pastore A, Sciarra A.
Ipertrofia prostatica benigna, disfunzione erettiva ed alfa1-antagonisti adrenergici.
Mediprint 2000;1:1-12

77. Sciarra A, Monti G, Schillaci O, Di Chiro C, Di Silverio F.
Clinical evidence of neuroendocrine differentiation in a case of prostate cancer with Bone marrow micrometastases.
Br. J. Urol. 2001;87:123-5.
IF 1.5

78. Sciarra A.
Eziopatogenesi dell’ipertrofia prostatica benigna: consensus paper.
Forum 2001; 11.1 suppl 1; 7-13

79. Sciarra A.
Terapia medica dell’ipertrofia prostatica benigna: come slezionare i pazienti?
Medico e Paziente 2002; 2:12-20

80. Sciarra A, Voria G, Pastore A, Mariotti G, Di Silverio F.
Histopathological aspects associated with the diagnosis of benign prostatic hyperplasia:clinical implications.
Urol Int 69;253-262; 2002
IF 0.5

81. Sciarra A, Voria G, Loreto A, Seccareccia F, Di Silverio F.
Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10.
Urol Int. 2003; 70(3): 186-94.
IF 0.5

82. Sciarra A, Voria G, Gentile V, Pastore A, Di Silverio F.
Variations of chromogranin A serum levels after radical retropubic prostatectomy for prostate adenocarcinoma
Arch Androl. 2003 Jan-Feb; 49(1): 39-48.
IF 0.7

83. Sciarra A, Voria G, Gentile V, Mariotti G, Di Silverio F.
Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?
BJU Int. 2003 Mar; 91(5): 438-45. Review
IF 1.8

84. Debruyne FMJ,  Akaza H,  Spermon JR,  Klotz, Di Silverio F, Sciarra A, Calais da Silva F, Habib F, Mahler C.
Innovative approaches in medical management of prostate cancer: hormones.
In: 3rd International Consultation on Prostate Cancer. June 2003. Murphy G et al Edt. Paris

85. Sciarra A, Monti S, Gentile V, Mariotti G, Di Silverio F.
Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Prostate. 2003 May 15; 55(3): 168-79.
IF 3.2

86. Di Silverio F, Voria G, Gentile V, Pastore A, Sciarra A.
Distribution of inflammation, premalignant lesions, incidental carcinoma in histologically confirmed BPH: a retrospective analysis.
Eur Urol. 2003 Feb; 43(2): 164-75.
IF 2.7

87. Di Silverio F, Sciarra A.
Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in  patients  with  androgen  ablation  refractory  prostate  cancer.
J Urol. 2003 Nov; 170(5): 1812-6.
IF 3.4

88. Sciarra A, Di Silverio F.
Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Urol Int. 2004;72(2):91-98
IF 0.4

89. Di Silverio F, Gentile V, Pastore A, Sciarra A.
Benign prostatic hyperplasia: What about a campaign for prevention?
Urol Int 2004; 72 (3); 179-188
IF 0.4

90. Sciarra A, Voria G, Pastore A, Di Silverio F.
Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive role of serum chromogranin A.
Prostate 2004;58(3) 421-428
IF 4.3

91. Sciarra A, Gentile V, Mariotti G, Voria G, De Matteis A, Di Silverio F.
Histopathological aspects of transitional cell carcinoma of the bladder:analysis on 20 years of experience.
Int . J. Urol. 2004 11(7):467-475
IF 0.9

92. Sciarra A, Di Silverio F.
Effect of non-steroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Urology 2004 ;63(3) 523-527
IF 3.0

93. Sciarra A, Bosman C, Monti S, Gentile V, Ciccariello M, Pastore A, Salvatori G, Fattore F, Di Silverio F.
Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate carcinoma.
J Urol.  2004 Nov;172(5 Pt 1):1775-83.
IF 3.4

94. Cerulli C, Sciarra A, Salvatori G, Di Silverio F.
Long term response to the combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
Urology 2004 ;64(6):1231-1233
IF3.0

95. Sciarra A, Cardi A, Salvatori G, D’Eramo G, Mariotti G, Di Silverio F.
Which patients are actually candidates for hormone therapy?
Int Braz.J.Urol.2004; 30(6):455-465

96. Di Silverio F, Bosman C, Monti S, Proietti Pannunzi L, Ciccariello M, Cardi A, Salvatori G, Sciarra A.
Combination Therapy With Rofecoxib And Finasteride In The Treatment Of Men With Lower Urinary Tract Symptoms (Luts) And Benign Prostatic Hyperplasia (BPH).
Eur Urol. 2005 Jan;47(1):72-8
IF 4.5

97. De Berardinis E, Vicini P, Salvatori G, Sciarra A, Gentile V, Di Silverio F.
Superselective embolization of bladder arteries in the treatment of intractable bladder haemorrage.
Int J Urol 2005; 12 (5); 503-5;
IF 0.9

98. Sciarra A, Monti S, Gentile V, Salciccia S, Autran Gomez A, Pannunzi L, Di Silverio F.
Chromogranin A expression in familial versus sporadic prostate cancer.
Urology 2005; 66(5):1010-1014
IF 3.0

99. Cerulli C, Sciarra A, Mazzone G, Autran Gomez A, Salciccia S, Di Silverio F.
Tumore primitivo carcinoide in rene a ferro di cavallo trattato con terapia conservativa.
Urologia 2005; 72(2) :243-245

100. Sciarra A, Mariotti G, Autran Gomez A, Di Silverio F.
Role of somatostatin analogues in the treatment of androgen ablation refractory prostate adenocarcinoma.
Cancer Therapy 2005;3:159-166

101. Sciarra A, Albanesi L, Fattore F, Mariotti G, Di Silverio F.
Androgen deprivation therapy and neuroendocrine differentiation in prostate carcinoma:an inductive role?
Eur. Kidney and Urol Disease 2006;1-7

102. Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Silverio F.
New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Int J Clin Pract 2006 ;60(4):462-474
IF 2.1

103. Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Silverio F.
New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Recent Res Devel Cancer 2005; 7: 1-18

104. Sciarra A, Salciccia S, Albanese L, Cardi A, D’Eramo G, Di Silverio F.
Use of cyclooxigenase -2 inhibitors for the prevention of urethral striature secondary to transurethral resection of the prostate.
Urology. 2005 Dec;66(6):1218-22
IF 3.0

105. Gentilucci A, Iannotta L, Parente U, Sciarra A, Cardillo MR, Di Silverio F.
Sarcoma epitelioide tipo prossimale retrovescicale.
Urologia 2006;73:244-246

106. Sciarra A, Cristini C, Gentilucci A, Parente U, Di Pierro GB, Antonini F, Alfarone A, Di Silverio F.
Ipertrofia prostatica benigna:una patologia in progressione. Ipotesi per una terapia preventiva.
Urologia 2006; 73 (3):257-265

107. Sciarra A.
Words of Wisdom: Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Eur Urol. 2007 Nov;52(5):1531-2.
IF 6.4

108. Sciarra A.
Neuroendocrine differentiation in prostate adenocarcinoma.
Eur Urol. 2007 Nov;52(5):1373.
IF 6.4

109. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez A, Gentilucci A, Gentile V.
Inflammation and chronic prostatic diseases: evidence for a link?
Eur Urol. 2007 Oct;52(4):964-72.
IF 6.4

110. Sciarra A, Autran Gomez A, Gentilucci A, Parente U, Salciccia S, Gentile V, Di Silverio F.
Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
Eur Urol. 2007 Aug;52(2):597-9.
IF 6.4

111. Sciarra A, Salciccia S.
New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?
Eur Urol. 2007 Oct;52(4):945-7.
IF 6.4

112. Monti S, Proietti Pannunzi L, Sciarra A, Lolli F, Falasco P, Poggi M, Celi FS, Toscano V.
The IGF axis in prostate cancer.
Curr Pharm Des. 2007;13(7):719-27. E046683
IF 1.7

113. Sciarra A.
Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Eur Urol. 2007 ;51(6):1485-7. Epub 2007 Jan 26.
IF 6.4

114. Prezioso D, Denis LJ, Klocker H, Sciarra A, Reis M, Naber K, Lobel B, Pacik D, Griffiths K.
Estrogens and aspects of prostate disease.
Int J Urol. 2007 ;14(1):1-16.
IF 1.1

115. Sciarra A, Lichtner M, Autran Gomez A, Nastroianni C, Rossi R, Mengoni F, Cristini C, Gentilucci A, Vullo V, Di Silverio F.
Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients.
Prostate. 2007 ;67(1):1-7.
IF 3.6

116. Sciarra A, Gentile V,  Autran Gomez A, Salciccia S, Gentilucci A, Monti S, Toscano V, Di Silverio F.
Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Endocr Relat Cancer. 2007 Sep;14(3):625-32.
IF 5.8

117. Sciarra A, Panebianco V, Di Silverio F, Salciccia S, Osimani M, Lisi D, Ciccariello M, Passariello R, Gentile V.
Role of dynamic contrast enhanced magnetic resonance imaging and proton MR spectroscopic imaging in thye detection of local recurrence after radicl prostatectomy for prostate cancer.
Eur Urol 2008;54(3):589-600. PMID: 18226441
IF 7.1

118. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Gentilucci A, Lisi D, Passariello R, Gentile V, Di Silverio F.
Complete Response to the Combination Therapy with Androgen Blockade and Somatostatin Analogue in a Patient with Advanced Prostate Cancer: Magnetic Resonance Imaging with 1H-Spectroscopy.
Eur Urol. 2008; 53:652-658
IF 7.1

119. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, Di Silverio F.
Prostate growth and inflammation.
J Steroid Biochem Mol Biol. 2008;108:254-260
IF 3.8

120. Sciarra A, Gentile V, De Matteis A, Dattilo C, Autran Gomez A, Salciccia S, Di Silverio F.
Long-term experience with an anatomical anterograde approach to radical prostatectomy: results in terms of positive margin rate.
Urol Int. 2008;80(2):151-6.
IF 1.1

121. Di Silverio F, Sciarra A, Gentile V.
Etoricoxib and intermitent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
Urology 2008 Feb 14. [Epub ahead of print] PMID: 18279940
IF 2.6

122. Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi L, Toscano V, Di Silverio F.
Comparison of chromogranin A, insulin-like growth factor1 and prostate specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
Urol Int 2008;80:68-73
IF 1.1

123. Sciarra A, Salciccia S, Panebianco V.
Proton Spectroscopic and Dynamic contrast enhanced magnetic resonance: a modern approach in prostate cancer imaging.
Eur Urol 2008 ,54(3);485-8. PMID: 18439748
IF 7.1

124. Sciarra A, Autran Gomez A, Salciccia S, Dattilo C, Ciccariello M, Gentile V, Di Silverio F.
Biopsy derived Gleason artifact and prostate volume: experience using ten samples in lager prostates.
Urol Int 2008 ;80(2):145-50.
IF 1.1

125. Sciarra A, Gentile V, Salciccia S, Alfarone A, Di Silverio F.
New antiangiogenic trageted therapy in advanced renal cell carcinoma (RCC).Current status and future prospects.
Rev Recent Clin Trial 2008;3 May:97-103 E191564
IF 0.2

126. Sciarra A.
Editorial comment on: MR-guided biopsy of the prostate: an overview of techniques and a systematic review.
Eur Urol. 2008 Sep;54(3):526-7.
IF 7.1

127. Di Silverio F, Sciarra A, Parente U.
Alfarone A,Von Heland M,Panebianco V, Passariello R. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.
Urol Int 2008 ;80(4):451- 3.
IF 1.1

128. Panebianco V, Sciarra A, Osimani M, Lisi D, Ciccariello M, Salciccia S, Gentile V, Di Silverio F, Passariello R.
2D and 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy with erectile function correlation.
Eur Radiol. 2009 Jan;19(1):220-9.
IF 4.1

129. Gentile V, Sciarra A, Parente U, Cardillo MR, Pierangeli A, Degener AM.
Human papilloma virus DNA detection, p53 and Ki67 expression in penile verrucous and squamous cell carcinomas in the same patient.
Sex Transm Dis. 2009 Jul;36(7):417-8. PubMed PMID: 19390495.
IF 2.7

130. Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A, Gentile V.
Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
Urol Int. 2009;82(2):147-51. Epub 2009 Mar 19. PubMed PMID: 19321999.
IF 1.1

131. Mariotti G, Sciarra A, Gentilucci A, Salciccia S, Alfarone A, Di Pierro G, Gentile V.
Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment.
J.Urol. 2009 Apr;181(4):1788-93. Epub 2009 Feb 23. PubMed PMID: 19233390.
IF 4.3

132. Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ, Stief C, Hricak H, Graser A.
Functional magnetic resonance imaging in prostate cancer.
Eur Urol. 2009 Apr;55(4):801-14. Epub 2009 Jan 21. Review. PubMed PMID: 19185981.
IF 8.7

133. Gazzaniga P, Gradilone A, de Berardinis E, Sciarra A, Cristini C, Naso G, di Silverio F, Frati L, Aglianò AM.
A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer.
BJU Int. 2009 Jul;104(2):184-8. Epub 2009 Jan 19. PubMed PMID: 19154503.
IF 3.3

134. Sciarra A.
Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
Eur Urol. 2009 Feb;55(2):320-1. Epub 2008 Sep 24. PubMed PMID: 18838210.
IF 6.5

135. Valerio M, Panebianco V, Sciarra A, Osimani M, Salsiccia S, Casciani L, Giuliani A, Bizzarri M, Di Silverio F, Passariello R, Conti F.
Classification of prostatic diseases by means of multivariate analysis on in vivo proton MRSI and DCE-MRI data.
NMR Biomed. 2009 Dec;22(10):1036-46. PubMed PMID: 19579258.
IF 3.3

136. Sciarra A, Panebianco V, Salciccia S, Alfarone A, Gentilucci A, Lisi D, Passariello R, Gentile V.
Use of 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy (RRP): a potential diagnostic tool for optimal management of erectile dysfunction after RRP.
J Sex Med. 2009 May;6(5):1430-7. PubMed PMID:19473289.
IF 1.3

137.  Panebianco V, Sciarra A, Di Martino M, Bernardo S, Vergari V, Gentilucci A, Catalano C, Passariello R.
Bladder carcinoma: MDCT cystography and virtual cystoscopy.
Abdom Imaging. 2010 Jun;35(3):257-64. Epub 2009 May 27. PubMed PMID: 19471998.
IF 1.9

138. Panebianco V, Sciarra A, Ciccariello M, Lisi D, Bernardo S, Cattarino S, Gentile V, Passariello R.
Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA).
Radiol Med. 2010 Dec;115(8):1314-29. Epub 2010 Sep 17. English, Italian. PubMed PMID: 20852963.
IF 1.6

139. Sciarra A.
Words of Wisdom. Re: Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles.
Maxeiner A, Adkins CB, Zhang Y, et al. Prostate 2010;70:710-7.
Eur Urol. 2010 Aug;58(2):315. PubMedPMID: 20845545.
IF 8.8

140. Sciarra A.
Words of Wisdom. Re: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB, Mulders PFA, Boerman DC, Oyen WJG, Oosterwijk. E .
Eur Urol. 2010 Aug;58(2):316. PubMed PMID:20845535.
IF  8.8

141. Sciarra A, Cristini C, Von Heland M, Salciccia S, Gentile V.
Randomized trial comparing an anterograde versus a retrograde approach to open radical prostatectomy: results in terms of positive margin rate.
Can Urol Assoc J. 2010 Jun;4(3):192-8. PubMed PMID: 20514284; PubMed Central PMCID: PMC2874595.
IF 0.8

142. Di Pierro GB, Sciarra A, Innocenzi M, Cristini C.
Rare case of multiple adenomatoid tumors arising from tunica vaginalis of testis and epididymis.
Actas Urol Esp. 2010 Jun;34(6):560-1. Spanish. PubMed PMID: 20510121.
IF 0.5

143. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone A, Bernardo S, Passariello R, Gentile V.
Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
Clin Cancer Res. 2010 Mar 15;16(6):1875-83. Epub 2010 Mar 2. PubMed PMID: 20197480.
IF 7.3

144. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Lisi D., Osimani M., Alfarone A., Gentilucci A., Parente U., Passariello R., Gentile V.
Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer.
Cancer Invest. 2010 May;28(4):424-32. PubMed PMID: 20073578.
IF 2.4

145. Sciarra A, Panebianco V, Salciccia S, Gentilucci A, Alfarone A, Dimare L, Lisi D, Catturino S, Di Pierro G, Von Heland M, Ciccariello M, Passariello R, Gentile V.
Value of magnetic resonance spectroscopy (MSR) and dynamic contrast-enhanced magnetic resonance (DCEMR) imaging for the characterization of high-grade prostatic intraepithelial neoplasia (HGPIN) foci.
Urol Oncol. 2011Nov;29(6):634-40. Epub 2009 Nov 13. PubMed PMID: 19914107.
IF  3.2

146. Sciarra A, Panebianco V, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone A, Mariotti G, Passariello R, Gentile V.
Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer.
Urol Oncol. 2011 Jan-Feb;29(1):12-20. Epub 2009 Sep 6. Review. PubMed PMID: 19734067.
IF 3.2

147. Sciarra A.
Monotherapy with tamsulosin.
Urologia. 2011 Oct-Dec;78(4):314-6. doi:10.5301/RU.2011.8792. Italian. PubMed PMID: 22101552.
IF 0.5

148. Sciarra A.
Combined dutasteride and tamsulosin.
Urologia. 2011 Oct- Dec;78(4):317-9. doi:10.5301/RU.2011.8793. Italian. PubMed PMID: 22101551.
IF 0.5

149. Sciarra A, Cattarino S, Gentilucci A, Alfarone A, Innocenzi M, Gentile V, Salciccia S.
Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
Urol Oncol. 2011 Jun 10. [Epub ahead of print] PubMed PMID: 21665494.
IF 3.2

150. Sciarra A, Innocenzi M, Ravaziol M, Minisola F, Alfarone A, Cattarino S, Monti G, Gentile V, Di Silverio F.
Neuroendocrine target therapies for prostate cancer
Urologia. 2011 Apr-Jun;78(2):137-41. doi: 10.5301/RU.2011.8335. Italian. PubMed PMID: 21574148.
IF 0.5

151. Sciarra A, Innocenzi M, Ravaziol M, Minisola F, Alfarone A, Cattarino S, Panebianco V, Buonocore V, Gentile V, Di Silverio F.
Current diagnostic procedure on neuroendocrine differentiation of prostate cancer
Urologia. 2011 Apr-Jun;78(2):132-6. doi: 10.5301/RU.2011.8336. Italian. PubMed PMID: 21574146.
IF 0.5

152. Sciarra A, Innocenzi M, Ravaziol M, Minisola F, Alfarone A, Cattarino S, Panebianco V, Buonocore V, Gentile V, Di Silverio F.
Role of neuroendocrine cells in prostate cancer progression
Urologia. 2011 Apr-Jun;78(2):126-31. doi: 10.5301/RU.2011.8337. Italian. PubMed PMID: 21574145.
IF 0.5

153. Panebianco V, Sciarra A, De Berardinis E, Busetto GM, Lisi D, Buonocore V, Gentile V, Di Silverio F, Passariello R.
PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations.
Anticancer Res. 2011 Apr;31(4):1399-405. PubMed PMID: 21508392.
IF 1.7

154. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A.
The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
Eur Urol. 2011 Jul;60(1):106-17. Epub 2011 Apr 9. Review. PubMed PMID: 21497433.
IF 8.5

155. Barentsz J, Dickinson L, Sciarra A.
Re: Axel Heidenreich. Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: not ready for routine use.
Eur Urol 2011;59:495-7. Eur Urol. 2011 Jul;60(1):e5-6. Epub 2011 Mar 22. PubMed PMID: 21429656.
IF 8.5

156. Palminteri E, Berdondini E, Shokeir AA, Iannotta L, Gentile V, Sciarra A.
Two-sided bulbar urethroplasty using dorsal plus ventral oral graft: urinary and sexual outcomes of a new technique.
J Urol. 2011 May;185(5):1766-71. Epub 2011Mar 21. PubMed PMID: 21420128.
IF 3.7

157. Sciarra A, Panebianco V, Salciccia S, Lisi D, Alfarone A, Gentilucci A, Parente U, Cattarino S, Passariello R, Gentile V.
Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR).
Urol Oncol. 2011 Mar 9. [Epub ahead of print] PubMed PMID: 21396849.
IF 3.2

158. Sciarra A, Cattarino S, Salciccia S, Alfarone A, Gentilucci A, Parente U, Mariotti G, Innocenzi M, Gentile V.
The emerging role of targeted therapy in renal cell carcinoma (RCC): Is it time for a neoadjuvant or an adjuvant approach?
Crit Rev Oncol Hematol. 2012 Feb;81(2):151-62. Epub 2011 Mar 8. PubMed PMID: 21388825.
IF  4.6

159. Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, Witjes JA.
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer.
Eur Urol. 2011 Jun;59(6):962-77. Epub 2011 Feb 23.PubMed PMID: 21367519.
IF  8.5

160. Sciarra A, Salciccia S, Nesi G, Cattarino S, Alfarone A, Gentilucci A, Gentile V.
Comparative effect of finasteride and dutasteride on chromogranin A levels.
Anticancer Res. 2010 Nov;30(11):4737-42. PubMed PMID: 21115933.
IF 1.6

161. Sciarra A, Cattarino S, Gentilucci A, Salciccia S, Alfarone A, Mariotti G, Innocenzi M, Gentile V.
Update on screening in prostate cancer based on recent clinical trials.
Rev Recent Clin Trials. 2011 Jan;6(1):7-15. Review. PubMed PMID:20868347.
IF 0.7

162. Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, Gentile V, Laghi A, Passariello R.
Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Eur J Radiol. 2012;81(4):700-8 PubMed PMID: 21330082
IF 2.5

163. Sciarra A, Salciccia S, Gentilucci A, Innocenzi M, Alfarone A, Cattarino S, Ravaziol M, Panebianco V.
Prostate cancer unit for an optimal management of prostate cancer unit.
Urologia. 2012 ;79(1):1-4. doi: 10.5301/RU.2012.8993. Italian. PubMed PMID: 22307530.
IF 0.5

164. Alfarone A, Panebianco V, Schillaci O, Salciccia S, Cattarino S, Mariotti G, Gentilucci A, Von Heland M, Passariello R, Gentile V, Sciarra A.
Comparative effect of multiparametric magnetic resonance and PET CT in the management of local recurrence after radical prostatectomy for prostate cancer.
Crit Rev Oncol Hematol. 2012 ;84(1):109-21 PubMedPMID: 22401991
IF 4.6

165. Sciarra A, Panebianco V, Cattarino S, Busetto GM, De Berardinis E, Ciccariello M, Gentile V, Salciccia S.
Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of urinary prostate cancer antigen 3 text in patients with elevated PSA levels and previous negative biopsy.
BJU Int 2012;110(11):1661-5 .doi:10.1111/j.1464-410X.2012.11146.x. PubMedPMID 22574540
IF 3.0

166. Panebianco V, Salciccia S, Cattarino S, Minisola F, Gentilucci A, Alfarone A, Ricciuti GP, Marcantonio A, Lisi D, Gentile V, Passariello R, Sciarra A.
Use of Multiparametric MR with Neurovascular Bundle Evaluation to Optimize the Oncological and Functional Management of Patients Considered for Nerve-Sparing Radical Prostatectomy.
J Sex Med. 2012 ;9(8): 2157-66 doi: 10.1111/j.1743- 6109.2012.02794.x. PubMedPMID 22642466
IF 3.5

167. Panebianco V, Sciarra A, Marcantonio A, Forte V, Biondi T, Laghi A, Catalano C.
Conventional imaging and Multiparametric Magnetic Resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer.
Q J Nucl Med Mol Imaging. 2012 Aug;56(4):331-42. PubMedPMID 23013663
IF 2.4

168. D’Eramo G, Fasanella D, Di Quilio F, Molnar P, Salciccia S, Sciarra A, Gentile V.
Comparison between ultrasound-guided and digital-guided anesthesia before prostatic biopsy.
Arch Ital Urol Androl. 2012 Dec;84(4):260-2.

169. Panebianco V, Iacovelli R, Barchetti F, Altavilla A, Forte V, Sciarra A, Cortesi E, Catalano C.
Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma.
Anticancer Res. 2013 Dec;33(12):5663-6.
IF 1.8

170. Sciarra A.
Words of wisdom. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Eur Urol. 2013 Dec;64(6):1014-5.
IF 12.4

171. Busetto GM, De Berardinis E, Sciarra A, Panebianco V, Giovannone R, Rosato S, D’Errigo P, Di Silverio F, Gentile V, Salciccia S.
Prostate cancer gene 3 andmultiparametric magnetic resonance can reduce unnecessary biopsies: decisioncurve analysis to evaluate predictive models.
Urology. 2013 Dec;82(6):1355-60.
IF 3.7

172. Busetto GM, De Berardinis E, Sciarra A, Giovannone R, Gentile V, Salciccia S, Panebianco V.
Reply: To PMID 24080222. Urology. 2013 Dec;82(6):1361-2.
IF 3.7

173. Innocenzi M, Casale P,  Alfarone A, Ravaziol M, Cattarino S, Grande P, Minisola F, Gentilucci A, Gentile V, Sciarra A.
Supernumerary kidney laparoscopically treated.
Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E772-4.
IF 1.9

174. Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F.
Intermittent androgen-deprivation therapy in prostatecancer: a critical review focused on phase 3 trials.
Eur Urol. 2013 Nov;64(5):722-30.
IF 12.4

175. Panebianco V, Barchetti F, Sciarra A, Marcantonio A, Zini C, Salciccia S, Collettini F, Gentile V, Hamm B, Catalano C.
In vivo 3D neuroanatomical evaluation of periprostatic nerve plexus with 3T-MR Diffusion Tensor Imaging.
Eur J Radiol. 2013 Oct;82(10):1677-82.
IF 2.1

176. Vitarelli A, Divenuto L, Fortunato F, Falco A, Pagliarulo V, Antonini G, Gentile V, Sciarra A, Salciccia S, Sansalone S, Di Placido MR, Garaffa G, Pagliarulo A.
Long term patient satisfaction and quality of life with AMS700CX inflatable penile prosthesis.
Arch Ital Urol Androl. 2013 Sep 26;85(3):133-7.

177. Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F.
The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).
BJU Int. 2013 Aug;112(4):432-41.
IF 3.1

178. Sciarra A, Von Heland M, Minisola F, Salciccia S, Cattarino S, Gentile V.
Thulium laser supported nephron sparing surgery for renal cell carcinoma.
J Urol. 2013 Aug;190(2):698-701
IF 3.7

179. Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, Tombolini V, Catalano C.
Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging.
Eur Radiol. 2013 Jun;23(6):1745-52.
IF 4.3

180. Sciarra A.
Editorial comment.
J Urol. 2013 Feb;189(2):499. .
IF 3.7

181. Sciarra A, Gentile V, Panebianco V.
Multidisciplinary management of Prostate Cancer: how and why.
Am J Clin Exp Urol. 2013 Dec 25;1(1):12-7. eCollection 2013. PubMedPMID 25374895

182. Sciarra A, Salciccia S.
A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy?
Eur Urol. 2014 May;65(5):905-6.
IF  13.9

183. Sciarra A.
Reply to Bernard Tombal’s letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. 
Eur Urol. 2014 Apr;65(4):e57.
IF 13.9

184. Sciarra A, Panebianco V.
Comparison in the follow-up of two patients with persistent elevated PSA and negative prostate biopsy.
Urologia. 2014 Jan-Mar;81(1):60-3.
IF 0.5

185. Sciarra A.
5ARI and PSA: therapeutic aspects.
Urologia. 2014 Sep 23;81 Suppl 24:17-20.
IF 0.5

186. Sciarra A, Gentile V, Cattarino S, Gentilucci A, Alfarone A, D’Eramo G, Salciccia S.
Oral ethinylestradiol in castration-resistant prostate cancer: A 10-year experience.
Int J Urol. 2015 ; 22(1): 99-103
IF 1.8

187. Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, Gallucci M, Tombolini V, Gentile V, Catalano C.
Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study.
Urol Oncol. 2015 Jan;33(1):17.e1-7. doi: 10.1016/j.urolonc.2014.09.013.
IF  2.9

188. Anzivino E, Rodio DM, Mischitelli M, Bellizzi A, Sciarra A, Salciccia S, Gentile V, Pietropaolo V.
High Frequency of JCV DNA Detection in Prostate Cancer Tissues.
Cancer Genomics Proteomics. 2015 Jul-Aug;12(4):189-200.
IF 2.8

189. Mariotti G, Salciccia S, Innocenzi M, Gentilucci A, Fasulo A, Gentile V, Sciarra A.
Recovery of Urinary Continence After Radical Prostatectomy Using Early vs Late Pelvic Floor Electrical Stimulation and Biofeedback-associated Treatment.  
Urology. 2015 Jul;86(1):115-20. doi: 10.1016/j.urology.2015.02.064.
IF 2.4

190. Silvestri I, Cattarino S, Aglianò AM, Collalti G, Sciarra A.
Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer.
Biomed Res Int. 2015;2015:794968. doi: 10.1155/2015/794968. Epub 2015 Jun
IF 2.1

191. Terrone C, Berruti A, Papotti M, Vavassori V, Sciarra A.
Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method.
Tumori. 2016; 102(5):514-520   doi: 10.5301/tj.5000389.
IF 1.2

192. Cattarino S, Salciccia S, Gentilucci A, Innocenzi M, Gentile V, Sciarra A.
Intermittent androgen deprivation in prostate cancer cases with biochemical progression after radical prostatectomy: Are we ready to treat?
Crit Rev Oncol Hematol. 2016 Mar;99:351-61. doi: 10.1016/j.critrevonc.2016.01.008. Epub 2016 Jan
IF 4.9

193. Sciarra A, Gentilucci A, Salciccia S, Pierella F, Del Bianco F, Gentile V, Silvestri I, Cattarino S.
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review.
J Inflamm (Lond). 2016 Nov 25;13:35
IF 2.5

194. Salciccia S, Gentilucci A, Cattarino S, Sciarra A.
GNRH-agonist or antagonist in the treatment of prostate cancer: a comparision based on oncological results.
Urologia. 2016 Nov 18;83(4):173-178. doi: 10.5301/uro.5000194.
IF 0.5

195. Silvestri I, Cattarino S, Giantulli S, Nazzari C, Collalti G, Sciarra A.
A Perspective of Immunotherapy for Prostate Cancer.
Cancers (Basel). 2016 Jul 7;8(7). pii: E64. doi: 10.3390/cancers8070064. Review
IF 5.3

196. Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M, Innocenzi M, Pierella F, Gentile V, Salciccia S, Cattarino S.
A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate
Medicine (Baltimore). 2016 Jul;95(27):e3845. doi: 10.1097/MD.0000000000003845.
IF 2.1

197. Sciarra A, Gentilucci A, Cattarino S, Innocenti M, Francesca DQ, Fasulo A, Von Heland M, Gentile V, Salciccia S.
Laparoscopic versus open radical prostatectomy in high prostate volume cases: impact on oncological and functional results.
Int Braz J Urol. 2016 Mar-Apr;42(2):223-33. doi: 10.1590/S1677-5538.IBJU.2015.0385.PMID: 27256175
IF 0.8

198. Noale M, Maggi S, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Maurizi Enrici R, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Tubaro A, Zagonel V, Zattoni F, Crepaldi G; Pros-IT CNR study group. Sciarra A.
Pros-IT CNR: an Italian prostate cancer monitoring project
Aging Clin Exp Res. 2017 Apr;29(2):165-172. doi: 10.1007/s40520-017-0735-6. Epub 2017 Feb 24. PMID:28236267
IF 2.1

199.  Sciarra A, Maggi M, Fasulo A, Salciccia S, Gentile V, Cattarino S, Gentilucci A.
Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation.
Urologia. 2017 Aug 1;84(3):158-164.
IF 0.5

200. Minisola F, Cipriani C, Colangelo L, Cilli M, Sciarra A, Von Heland M, Nieddu L, Anastasi E, Pascone R, Fassino V, Diacinti D, Longo F, Minisola S, Pepe J.
Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study.
Endocrine. 2018 Feb;59(2):338-343.
IF 3.2

201. Valentino A, Calarco A, Di Salle A, Finicelli M, Crispi S, Calogero RA, Riccardo F, Sciarra A, Gentilucci A, Galderisi U, Margarucci S, Peluso G.
Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.
Oncogene. 2017 Oct 26;36(43):6030-6040
IF 6.8

202. Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, Lugini ., Borsellino G, Gentilucci A, Pierella F, Marzio V, Sciarra A, Battistini L, Fais S.
Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.
Cancer Lett. 2017 Sep 10;403:318-329.
IF 6.5

203. Del Monte M, Leonardo C, Salvo V, Grompone MD, Pecoraro M, Stanzione A, Campa R, Vullo F, Sciarra A, Catalano C, Panebianco V.
MRI/US fusion-guided biopsy: performing exclusively targeted biopsies for the early detection of prostate cancer.
Radiol Med. 2018 Mar;123(3):227-234.
IF 1.4

204. Salciccia S, Sciarra A, Polese M, Giorgio A, Maggi M, Gentilucci A, Ciccariello M, D’Eramo G, Shahabadi H, Lai S, Ricciuti GP.
Loss of Renal Function After Retrograde Ureteral Placement of an Allium Stent for Severe Ureteral Stricture.
J Endourol Case Rep. 2018 Jan 1;4(1):9-11

205.  Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, Campa R, Indino EL, Barchetti F, Sciarra A, Leonardo C, Gallucci M, Catalano C.
Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What’s Next?
Eur Urol. 2018 ;74(1):48-54 . pii: S0302-2838(18)30183-0. doi: 10.1016/j.eururo.2018.03.007.
IF 17.2

206. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators.Sciarra A
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.
IF 70.6

207. Sciarra A, Gentilucci A, Salciccia S, Von Heland M, Ricciuti GP, Marzio V, Pierella F, Musio D, Tombolini V, Frantellizzi V, Pasquini M, Maraone A, Guandalini A, Maggi M.
Psychological and functional effect of different primary treatments for prostate cancer: A comparative prospective analysis.
Urol Oncol. 2018; 36(7)340 pii: S1078-1439(18)30121-2. doi: 10.1016/j.urolonc.2018.03.022. [Epub ahead of print] PMID: 29706458
IF 2.8

208. Porreca A, Noale M, Artibani W. Bassi PF,Bertoni F ; Pros IT group Sciarra A.
Disease specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study.
Health of Quality Life Outcomes 2018; 16(1):122. PMID 29898750
IF 2.3

209. Del Giudice F, Busetto GM, Chung BI, Conti SL, Ferro M, Maggi M, Sciarra A, Perito PE, Gross MS, Antonini G, De Berardinis E.
Non-ischemic priapism following recurrent idiopathic ischemic priapism treated successfully with selective arterial embolization and postoperative vacuum therapy before delayed inflatable penile prosthesis placement: A single case report.
IJU Case Rep. 2018 Sep 20;1(1):13-15. doi: 10.1002/iju5.12019. eCollection 2018 Nov.PMID: 32743355
IF 2.1

210. Maggi M, Gentilucci A, Salciccia S,Gatto A, Gentile V,Colarieti A, Von Heland M, Busetto GM, Del Giudice F, Sciarra A. 
Psychological impact of different primary treatments for prostate cancer : A critical analysis.
Andrologia 2019; 51(1):e13157 PMID 30281167
IF 1.9

211. Salciccia S, Sciarra A, Pierella F, Leoncini PP, Vitullo P, Polese M, maggi M, Perugia G, Di Marco F, Ricciuti GP.
Predictors of hospitalization after ureteroscopy plus elective double J stent as an outpatients procedure.
Urol Int 2019; 102(2): 167-174
IF 1.4

212. Cattarino S, Forte V, Salciccia S, Drudi FM, Cantisani V, Sciarra A, Fasulo A, Ciccariello M.
MRI ultrasound fusion biopsy in prostate cancer detection; are randomized trials reproducible in everyday clinical practice?
Urologia 2019; 86(1):9-16
IF 0.5

213. Sciarra A, Gentilucci A, Silvestri I, Salciccia S, Cattarino S, Scarpa S, Gatto A, Frantellizzi V, Von Heland M, Ricciuti GP, Del Giudice F, Maggi M.
Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castration resistant prostate cancer: A critical review.
Medicine 2019 ; 98(19): e15608. PMID 31083254
IF 1.5

214. Chi KN, Agarwal N, Bjartell A, Chung BU; TITAN investigators Sciarra A
Apalutamide for metastatic castration sensitive prostate cancer.
N Engl J Med 2019; 381(1):13-24. PMID 31150574
IF 74.7

215. Agarwal N1, McQuarrie K2, Bjartell A3, Chowdhury S4, Pereira de Santana Gomes AJ5, Chung BH6, Özgüroğlu M7, Juárez Soto Á8, Merseburger AS9, Uemura H10, Ye D11, Given R12, Cella D13, Basch E14, Miladinovic B15, Dearden L16, Deprince K17, Naini V18, Lopez-Gitlitz A19, Chi KN20; TITAN investigators (Sciarra A)
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Lancet Oncol. 2019 Nov;20(11):1518-1530. doi: 10.1016/S1470-2045(19)30620-5. Epub 2019 Sep 29.
IF 33.7

216. Antonelli A, Palumbo C, Noale M and the ProsIT groups, Sciarra A.
Impact of surgical approach on patient- reported outcomes after radical prostatectomy: a propensity score-weighted analysis from a multicenter prospective observational study.
Urol Int. 2019; 103:1: 8-18
IF 1.7

217. Logozzi M, Angelini DF, Giuliani A, Mizzoni D, Di Raimo R, Maggi M, Gentilucci A, Marzio V, Salciccia S, Borsellino G, Battistini L, Sciarra A, Fais S.
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
Cancers (Basel). 2019 Sep 27;11(10). pii: E1449. doi: 10.3390/cancers11101449.
IF 6.1

218. Buglione M, Noale M, Bruni A, Antonelli A, bertoni F, Corvo R, Ricardi V, Pros-IT CNR Gropus: Sciarra A
Treatment path for localized prostate cancer in Italy:The results of a multidisciplinary, observational, prospective study (Pros-It-CNR).
PlosONE 2019; 14(11): e0224151
IF 2.7

219. Del Giudice F, Busetto GM, De Berardinis E, Sperduti I, Ferro M, Maggi M, Gross MS, Sciarra A, Eisenberg ML.
A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility.
Asian J Androl. 2020;22(4):360-367 doi: 10.3389/fendo.2019.00540
IF 2.4

220.  Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, Sciarra A, Leonardo C, Gallucci M, Catalano C, Catto JWF, Panebianco V.
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Eur Urol. 2020;77(1):101-107 doi: 10.1016/j.eururo.2019.09.029. [Epub ahead of print]
IF 17.9

221. Maggi M, Panebianco V, Mosca A, Salciccia S, Gentilucci A, Di Pierro G, Busetto GM,Barchetti G, Campa R, Sperduti I, Del Giudice F, Sciarra A
Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis
Eur Urol Focus 2020; 6(3):463-478;  doi  10.1016/j.euf.2019.06.014. PMID 31279677
IF 4.8

222. Logozzi M, Mizzoni D, Capasso C, Del Prete S, Di Raimo R, Falchi M, Angelini DF, Sciarra A, Maggi M, Supuran CT, Fais S.
Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.
J Enzyme Inhib Med Chem. 2020 Dec;35(1):280-288. doi: 10.1080/14756366.2019.1697249
IF 4.6.

223. Giganti F, Pecoraro M, Stavrinides V, Stabile A, Cipollari S, Sciarra A, Kirkham A, Allen C, Punwani S, Emberton M, Catalano C, Moore CM, Panebianco V.
Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study.
Eur Radiol. 2020; 30(4): 2082-90  doi: 10.1007/s00330-019-06557-2. [Epub ahead of print]
IF 4.1

224. Antonelli A, Palumbo C, Noale M, Artibani W, Bassi P, Bertoni F, Bracarda S, Bruni A, Corvò R, Gacci M, Magrini SM, Montironi R, Porreca A, Tubaro A, Zagonel V, Maggi S; and the Pros-IT CNR study group: A.Sciarra.
Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study).
Minerva Urol Nefrol. 2020 Jan 7. doi: 10.23736/S0393-2249.19.03637-3.
IF 3.5

225. Busetto GM, Del Giudice F, D’Agostino D, Romagnoli D, Minervini A, Rocco B, Antonelli A, Celia A, Schiavina R, Cindolo L, Chung BI, Kim JH, Maggi M, Sciarra A, De Berardinis E, Porreca A.
Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature.
Arch Ital Urol Androl. 2020 Jan 13;91(4):205-210. doi: 10.4081/aiua.2019.4.205. PMID:31937082
IF 0.7

226. Busetto GM, Del Giudice F, Virmani A, Sciarra A, Maggi M, Ferro M, Porreca A, Chung BI, Agarwal A, De Berardinis E.
Body mass index and age correlate with antioxidant supplementation effects on sperm quality: Post hoc analyses from a double-blind placebo-controlled trial.
Andrologia. 2020 Feb 4:e13523. doi: 10.1111/and.13523. [Epub ahead of print] PMID:32017167
IF 1.9

227. Busetto GM, Del Giudice F, Maggi M, Antonini G, D’Agostino D, Romagnoli D, Del Rosso A, Giampaoli M, Corsi P, Palmer K, Ferro M, Lucarelli G, Terracciano D, De Cobelli O, Sciarra A, De Berardinis E, Porreca A.
Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity.
Aging (Albany NY). 2020; 12(5):4337-4347. doi: 10.18632/aging.102883. [Epub ahead of print]
IF 4.8

228.  Sciarra A, Salciccia S, Maggi M, Del Giudice F, Busetto GM, Musio D, Ciardi A, Catalano C, Cortesi E, Panebianco V.
Elective procedures for prostate cancer in the time of Covid-19: a multidisciplinary team experience.
Prostate Cancer Prostatic Dis. 2020 May 18:1-3. doi: 10.1038/s41391-020-0240-4. Online ahead of print.PMID: 32425655
IF 4.3

229. Busetto GM, Porreca A, Del Giudice F, Maggi M, D’Agostino D, Romagnoli D, Musi G, Lucarelli G, Palmer K, Colonna di Paliano A, Muto M, Hurle R, Terracciano D, de Cobelli O, Sciarra A, De Berardinis E, Ferro M.
SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?
Urol Int. 2020 Jun 9:1-13. doi: 10.1159/000509065. Online ahead of print.PMID: 32516772
IF 1.7

230. Anastasi E, Maggi M, Tartaglione S, Angeloni A, Gennarini G, Leoncini PP, Sperduti I, Di Lascio G, De Stefano V, Di Pierro GB, Del Giudice F, Busetto GM, De Berardinis E, Sciarra A.
Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
Diagn Cytopathol. 2020 Jun 20. doi: 10.1002/dc.24530. Online ahead of print.PMID: 32562513
IF 1.2

231.  Flammia S, Salciccia S, Tufano A, Busetto GM, Ricciuti GP, Sciarra A.
How urinary stone emergencies changed in the time of COVID-19?
Urolithiasis. 2020 May 28:1-3. doi: 10.1007/s00240-020-01198-3. Online ahead of print.PMID: 32468127
IF 2.5

232. Panebianco V, Del Giudice F, Leonardo C, Sciarra A, Catalano C, Catto JWF.
VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic.
Eur Urol. 2020 Jul;78(1):e18-e20. doi: 10.1016/j.eururo.2020.04.043. Epub 2020 Apr 27.PMID: 32360050
IF 17.9

233. Del Giudice F, Kasman AM, Ferro M, Sciarra A, De Berardinis E, Belladelli F, Salonia A, Eisenberg ML.
Clinical correlation among male infertility and overall male health: A systematic review of the literature.
Investig Clin Urol. 2020 Jul;61(4):355-371. doi: 10.4111/icu.2020.61.4.355. Epub 2020 Jun 8.PMID: 32665992
IF 1.7

234. Porreca A, Bianchi FM, Salvaggio A, D’Agostino D, Del Rosso A, Romagnoli D, Corsi P, Colicchia M, Barbaresi U, Bianchi L, Giampaoli M, Schiavina R, Palmer K, Del Giudice F, Maggi M, Ferro M, Sciarra A, De Berardinis E, Busetto GM.
Prognostic performance of magnetic resonance imaging-guided biopsy in defining prostate cancer anterior lesions.
World J Urol. 2021;39(5):1473-79 . doi: 10.1007/s00345-020-03335-4. Online ahead of print.PMID: 32621027
IF 3.2

235. Busetto GM, Del Giudice F, Maggi M, De Marco F, Porreca A, Sperduti I, Magliocca FM, Salciccia S, Chung BI, De Berardinis E, Sciarra A.
Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy.
World J Urol. 2020 Jul 17. doi: 10.1007/s00345-020-03359-w. Online ahead of print.PMID: 32681273
IF 3.2

236. Gacci M, Artibani W, Bassi P, Bertoni F, Bracarda S, Briganti A, Carmignani G, Carmignani L, Conti G, Corvò R, De Nunzio C, Fusco F, Graziotti P, Greco I, Maggi S, Magrini SM, Mirone V, Montironi R, Morgia G, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Russo G, Salonia A, Simonato A, Serni S, Tomasini D, Tubaro A, Zagonel V, Crepaldi G; MIRROR-SIU/LUNA Study Group and the Pros-IT CNR Study Group (Sciarra A).
How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study.
World J Urol. 2021; 39(5):1445-52 Aug 1. doi: 10.1007/s00345-020-03350-5. Online ahead of print.PMID: 32740803
IF 3.2

237. Porreca A, Del Giudice F, Giampaoli M, D’Agostino D,Romagnoli D, Corsi P, Maggi M, Schiavina R, De berardinis E, Sciarra A, Busetto GM.
Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in me with previous negative biopsy or enrolled in active surveillance programs.
Medicine 2020; 99;37
IF 1.5

238. Flammia S, Frisenda M, Maggi M, Magliocca FM, Ciardi A, Panebianco V, De Berardinis E, Salciccia S, Di Pierro GB, Gentilucci A, Del Giudice F, Busetto GM, Gallucci M, Sciarra A.
Cribriform pattern does not have a significant impact in Gleason Score ≥7/ISUP Grade ≥2 prostate cancers submitted to radical prostatectomy.
Medicine (Baltimore). 2020 Sep 18;99(38):e22156. doi: 10.1097/MD.0000000000022156.PMID: 32957339
IF 1.5

239. Salciccia S, Del Giudice F, Gentile V, Mastroianni CM, Pasculli P, Di Lascio G, Ciardi MR, Sperduti I, Maggi M, De Berardinis E, Eisenberg ML, Sciarra A.
Interplay between male testosterone levels and the risk for subsequent invasive respiratory assistance among COVID-19 patients at hospital admission.
Endocrine. 2020 Oct 8. doi: 10.1007/s12020-020-02515-x. Online ahead of print.PMID: 33030665
IF 3.2

240. Salciccia S, Del Giudice F, Maggi M, Eisenberg M, Chung BI, Conti SL, Kasman A, Vilson FL, Ferro M, Lucarelli G, Viscuso P, Di Pierro G, Busetto GM, Luzi M, Sperduti I, Ricciuti GP, De Berardinis E, Sciarra A.
Safety and Feasibility of Outpatient Surgery in Benign Prostatic Hyperplasia: a Systematic Review and Meta-analysis.
J Endourol. 2021; 35(4):395-408. Oct 21. doi: 10.1089/end.2020.0538. Online ahead of print.PMID: 33081521
IF 2.3

241.  Maggi M, Cowan JE, Fasulo V, Washington SL 3rd, Lonergan PE, Sciarra A, Nguyen HG, Carroll PR.
The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
J Urol. 2020 Dec;204(6):1222-1228. doi: 10.1097/JU.0000000000001313. Epub 2020 Nov 6.PMID: 33157570
IF 5.9

242. Salciccia S, Del Giudice F, Eisemberg M, Mastroianni CM, de Berardinis E,Ricciuti G, Maggi M, Sciarra A.
Androgen deprivation therapy and SARS-Cov_2 infection:the potential double-face role of testosterone.
Therapeutic advances in endocrinology and metabolism. 2020, 11:1-3
IF 2.1

243. Procopio G, Chiuri VE, Giordano M, Mantini G, Maisano R, Bordonaro R, Calvani N, Facchini G, De Placido S, Airoldi M, Sbrana A, Gasparro D, Ludovico GM, Guglielmini P, Naglieri E, Fagnani D, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D.
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study.
Ther Adv Med Oncol. 2020 Oct 29;12:1758835920968725. doi: 10.1177/1758835920968725. eCollection 2020.PMID: 33193831
IF 6.8

244.  Busetto GM, Del Giudice F, Mari A, Sperduti I, Longo N, Antonelli A, Cerruto MA, Costantini E, Carini M, Minervini A, Rocco B, Artibani W, Porreca A, Porpiglia F, Damiano R, De Sio M, Arcaniolo D, Cimino S, Russo GI, Lucarelli G, Di Tonno P, Gontero P, Soria F, Trombetta C, Liguori G, Scarpa RM, Papalia R, Terrone C, Borghesi M, Verze P, Madonia M, De Lisa A, Bove P, Guazzoni G, Lughezzani G, Racioppi M, Di Gianfrancesco L, Brunocilla E, Schiavina R, Simeone C, Veccia A, Montorsi F, Briganti A, Dal Moro F, Pavone C, Serretta V, Di Stasi SM, Galosi AB, Schips L, Marchioni M, Montanari E, Carrieri G, Cormio L, Greco F, Musi G, Maggi M, Conti SL, Tubaro A, De Berardinis E, Sciarra A, Gallucci M, Mirone V, de Cobelli O, Ferro M.
How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?
Front Surg. 2020 Nov 24;7:563006. doi: 10.3389/fsurg.2020.563006.
IF 1.8

245. Maggi M, Pirola GM, Absil F, De Plaen E, Mosca A, Salciccia S, Sciarra A, Bollen R.
Erective function recovery after laparoscopic decompression of pudendal artery and nerve: a documented case report.
Central European Journal of Urology 2020; 73(4): 1-3
IF 1.3

246. Lai S, Sciarra A, Pierella F, Pastore S, Piloni L, Salciccia S, Perrotta AM, Protopapa P, Pintus G, Ricciuti GP, Ciccariello M, Von Heland M.
Chronic kidney disease and urological disorders: an overview.
Current Signal Transduction therapy 2020; 15(2) 224-231

247.  Sciarra A, Maggi M, Salciccia S, Nicolai A, Tortorella E, Giantulli S, Magliocca FM, Silvestri I, Taglieri L, Cattarino S, Scarpa S
Tissue Expression of Androgen Receptor Splice Variant 7 at Radical Prostatectomy Predicts Risk of Progression in Untreated Nonmetastatic Prostate Cancer.
Oncology 2021;18:1-5   PMID: 33461196
IF 2.6

248. Porreca A, D’Agostino D, Romagnoli D, Del Giudice F, Maggi M, Palmer K, Falabella R, De Berardinis E, Sciarra A, Ferro M, Artibani W, Mirone V, Busetto GM.
The Clinical Efficacy of Nitrofurantoin for Treating Uncomplicated Urinary Tract Infection in Adults: A Systematic Review of Randomized Control Trials.
Urol Int. 2021 Feb 3:1-10. doi: 10.1159/000512582. Online ahead of print.PMID: 33535221 Review.
IF 1.6

249. Sciarra A, Maggi M, Del Proposto A, Magliocca FM, Ciardi A, Panebianco V, De Berardinis E, Salciccia S, Di Pierro GB, Gentilucci A, Kasman AM, Chung BI, Ferro M, de Cobelli O, Del Giudice F, Busetto GM, Gallucci M, Frisenda M.
Impact of uni- or multifocal perineural invasion in prostate cancer at radical prostatectomy.
Transl Androl Urol. 2021 Jan;10(1):66-76. doi: 10.21037/tau-20-850.PMID: 33532297
IF 2.3

250. Del Giudice F, Glover F, Belladelli F, De Berardinis E, Sciarra A, Salciccia S, Kasman AM, Chen T, Eisemberg ML.
Association of daily step count and serum testosterone among men in the United States.
Endocrine 2021; 2021 Feb 12.doi: 10.1007/s12020-021-02631-2. Online ahead of print.
IF 3.2

251. Del Giudice F, Busetto GM, Gross MS, Maggi M, Sciarra A, Salciccia S, Ferro M, Sperduti I, Flammia S, Canale V, Chung BI, Conti SL, Eisenberg ML, Skinner EC, De Berardinis E.
Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis.
J Cancer Res Clin Oncol. 2021;147(10):3073-80 Mar 6. doi: 10.1007/s00432-021-03571-0. Epub ahead of print. PMID: 33675400.
IF 3.2

252. Ferro M, Lucarelli G, DE Cobelli O, Del Giudice F, Musi G, Mistretta FA, Luzzago S, Busetto GM, Buonerba C, Sciarra A, Conti S, Porreca A, Battaglia M, Ditonno P, Manfredi M, Fiori C, Porpiglia F, Terracciano D.
The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology.
Minerva Urol Nephrol. 2021 Mar 26. doi: 10.23736/S2724-6051.21.04098-4. Online ahead of print.PMID: 33769016
IF 3.5

253. Cerrato A, Bedia C, Capriotti AL, Cavaliere C, Gentile V, Maggi M, Montone CM, Piovesana S, Sciarra A, Tauler R, Lagana’ A.
Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine.
Analytica Chimica Acta 2021; 1158;8:
IF 5.9

254. Salciccia S, Eisenberg ML, Maggi M, Lai S, Mastroianni CM, Pasculli P, Ciardi MR, Canale V, Ferro M, Busetto GM, De Berardinis E, Ricciuti GP, Sciarra A, Del Giudice F.
Modeling the Contribution of Male Testosterone Levels to the Duration of Positive COVID Testing among Hospitalized Male COVID-19 Patients.
Diagnostics (Basel). 2021 Mar 24;11(4):581. doi: 10.3390/diagnostics11040581. PMID: 33804969.
IF 3.1

255. Sciarra A, Viscuso P, Arditi A, Mariotti G, De Berardinis E, Di Pierro GB, Canale V, Gentilucci A, Busetto GM, Maggi M, Eisenberg ML, Vilson F, Chung BI, Ferro M, Salciccia S, Del Giudice F.
A Biofeedback guided program or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: a meta-analysis and systematic review.
Int J Clin Pract. 2021 Apr 2:e14208. doi: 10.1111/ijcp.14208. Epub ahead of print. PMID: 33811418.
IF 2.4

256. Del Giudice F Alex M K, Tony C, De Berardinis E, Busetto GM, Sciarra A, Ferro M, Giuseppe L, Federico B, Andrea S, Michael L E.
The Association between Mortality and Male Infertility: Systematic Review and Meta-analysis.
Urology. 2021 Apr 2:S0090-4295(21)00287-9. doi: 10.1016/j.urology.2021.02.041. Epub ahead of print. PMID: 33819517.
IF: 1.9

257. Sciarra A, Di Lascio G, Del Giudice F, Leoncini PP, Salciccia S, Gentilucci A, Porreca A, Chung BI, Di Pierro G, Busetto GM, De Berardinis E, Maggi M.
Comparison of the clinical usefulness of different urinary tests for the initial diagnosis of bladder cancer.
Current urology 15(1):22-32, March 2021 doi: 10.1097/CU9.0000000000000012

258. Salciccia S, Capriotti AL, Laganà A, Fais S, Logozzi M, De Berardinis E, Busetto GM, Di Pierro GB, Ricciuti GP, Del Giudice F, Sciarra A, Carroll PR, Cooperberg MR, Sciarra B, Maggi M.
Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes.
Int J Mol Sci. 2021 Apr 22;22(9):4367. doi: 10.3390/ijms22094367. PMID: 33922033.

259. Maggi M, Del Giudice F, Falagario UG, Cocci A, Russo GI, Di Mauro M, Sepe GS, Galasso F, Leonardi R, Iacona G, Carroll PR, Cooperberg MR, Porreca A, Ferro M, Lucarelli G, Terracciano D, Cormio L, Carrieri G, De Berardinis E, Sciarra A, Busetto GM.
SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study.
Cancers (Basel). 2021 Apr 23;13(9):2047. doi: 10.3390/cancers13092047. PMID: 33922626.

260. Bruno SM, Falagario UG, d’Altilia N, Recchia M, Mancini V, Selvaggio O, Sanguedolce F, Del Giudice F, Maggi M, Ferro M, Porreca A, Sciarra A, De Berardinis E, Bettocchi C, Busetto GM, Cormio L, Carrieri G.
PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study.
Front Oncol. 2021 May 20;11:693684. doi: 10.3389/fonc.2021.693684. eCollection 2021.PMID: 34094990

261. Maggi M, Salciccia S, Del Giudice F, Busetto GM, Falagario UG, Carrieri G, Ferro M, Porreca A, Di Pierro GB, Fasulo V, Frantellizzi V, De Vincentis G, De Berardinis E, Sciarra A.
A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data.
Front Oncol. 2021 Jun 8;11:700258. doi: 10.3389/fonc.2021.700258. eCollection 2021.PMID: 34169003

262. Sciarra A, Busetto GM, Salciccia S, Del Giudice F, Maggi M, Crocetto F, Ferro M, De Berardinis E, Scarpa RM, Porpiglia F, Carmignani L, Damiano R, Artibani W, Carrieri G.
Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies.
Front Endocrinol (Lausanne). 2021 Jun 14;12:695170. doi: 10.3389/fendo.2021.695170. eCollection 2021.PMID: 34194398

263. Pirola GM, Maggi M, Castellani D, Sciarra A, Rubilotta E, Gubbiotti M. A
Cost-Benefit Analysis of Bipolar TURP for the Treatment of Bladder Outflow Obstruction.
Res Rep Urol. 2021 Jul 9;13:487-494. doi: 10.2147/RRU.S277480. PMID: 34268258; PMCID: PMC8276822.

264. Sciarra A, Frisenda M, Maggi M, Magliocca FM, Ciardi A, Panebianco V, Berardinis E, Salciccia S, Di Pierro GB, Gentilucci A, Del Giudice F, Busetto GM, Tufano A.
Prospective comparative trial on nerve-sparing radical prostatectomy using a robot-assisted versus laparoscopic technique: expectation versus satisfaction and impact on surgical margins.
Cent European J Urol. 2021;74(2):169-177. doi: 10.5173/ceju.2021.0017.R3. Epub 2021 May 7. PMID: 34336234; PMCID: PMC8318028.

265. Salciccia S, Del Giudice F, Eisenberg ML, Mastroianni CM, De Berardinis E, Ricciuti GP, Viscuso P, Zingaropoli A, Pasculli P, Ciardi MR, Sciarra A, Maggi M.
Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection.
Ther Adv Endocrinol Metab. 2021 Apr 22;12:20420188211010105. doi: 10.1177/20420188211010105. eCollection 2021.PMID: 34104394

266. Sciarra A, Fiori C.
Enzalutamide for castration resistant prostatic cancer: “real-life” matters!
Minerva Urol Nephrol. 2021 Aug;73(4):552-553. doi: 10.23736/S2724-6051.21.04632-2.PMID: 34494417

267. Di Pierro GB, Lemma A, Di Lascio G, El Motassime A, Grande P, Di Giulio I, Salciccia S, Maggi M, Antonini G, De Berardinis E, Cristini C, Sciarra A.
Primary versus revision implant for inflatable penile prosthesis: A propensity score-matched comparison.
Andrologia. 2021 Sep 9:e14240. doi: 10.1111/and.14240. Online ahead of print.PMID: 34498769

268. Ferro M, de Cobelli O, Vartolomei MD, Lucarelli G, Crocetto F, Barone B, Sciarra A, Del Giudice F, Muto M, Maggi M, Carrieri G, Busetto GM, Falagario U, Terracciano D, Cormio L, Musi G, Tataru OS.
Prostate Cancer Radiogenomics-From Imaging to Molecular Characterization.
Int J Mol Sci. 2021 Sep 15;22(18):9971. doi: 10.3390/ijms22189971.PMID: 34576134

269. Del Monte M, Cipollari S, Del Giudice F, Pecoraro M, Bicchetti M, Messina E, Dehghanpour A, Ciardi A, Sciarra A, Catalano C, Panebianco V.
MRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques.
Br J Radiol. 2021 Oct 5:20210528. doi: 10.1259/bjr.20210528. Online ahead of print.PMID: 34609900

270. Panebianco V, Paci P, Pecoraro M, Conte F, Carnicelli G, Besharat ZM, Catanzaro G, Splendiani E, Sciarra A, Farina L, Catalano C, Ferretti E.
Network Analysis Integrating microRNA Expression Profiling with MRI Biomarkers and Clinical Data for Prostate Cancer Early Detection: A Proof of Concept Study.
Biomedicines. 2021 Oct 14;9(10):1470. doi: 10.3390/biomedicines9101470.PMID: 34680592

271. Ferro M, Del Giudice F, Carrieri G, Sciarra A, Catellani M, de Cobelli O.
The impact of sars-cov-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis
Cancers 2021, 13(21), 5276

272. Logozzi M, Mizzoni D, Di Raimo R, Giuliani A, Maggi M, Sciarra A, Fais S.
Plasmatic Exosome Number and Size Distinguish Prostate Cancer Patients From Healthy Individuals: A Prospective Clinical Study.
Front Oncol. 2021 Oct 20;11:727317. doi: 10.3389/fonc.2021.727317. eCollection 2021.PMID: 34745949

273. Scafuri L, Sciarra A, Crocetto F, Ferro M, Buonerba C, Ugliano F, Guerra G, Sanseverino R, Lorenzo GD.
Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?
Future Sci OA. 2021 Oct 28;7(9):FSO770. doi: 10.2144/fsoa-2021-0092. PMID: 34737893; PMCID: PMC8558855.

274.  Salciccia S, Sciarra A, Moriconi M, Maggi M, Viscuso P, Rosati D, Frisenda M, Di Pierro GB, Canale V, Bevilacqua G, Nesi G, Del Giudice F, Gentilucci A, Cattarino S, Mariotti G.
How to Predict Outcomes from a Biofeedback and Pelvic Floor Muscle Electric Stimulation Program in Patients with Urinary Incontinence after Radical Prostatectomy.
J Clin Med. 2021 Dec 27;11(1):127. doi: 10.3390/jcm11010127.PMID: 35011866

275. Salciccia S, Rosati D, Viscuso P, Canale V, Scarrone E, Frisenda M, Catuzzi R, Moriconi M, Asero V, Signore S, De Dominicis M, Emiliozzi P, Carbone A, Pastore AL, Fuschi A, Di Pierro GB, Gentilucci A, Cattarino S, Mariotti G, Busetto GM, Ferro M, De Berardinis E, Ricciuti GP, Panebianco V, Magliocca FM, Del Giudice F, Maggi M, Sciarra A.
Influence of operative time and blood loss on surgical margins and functional outcomes for laparoscopic versus robotic-assisted radical prostatectomy: a prospective analysis
Central European Journal Urology Issue:2021, Vol. 74, No. 4

276. Bauckneht M, Rebuzzi SE, Signori A, Frantellizzi V, Murianni V, Lodi Rizzini E, Mascia M, Lavelli V, Donegani MI, Ponzano M, Gaudiano A, Stazza ML, Licari M, Cavallini L, Laghi V, Cindolo L, Maggi M, Sciarra A, Mammucci P, Sambuceti G, Costa RP, Spanu A, Rubini G, Monari F, De Vincentis G, Fornarini G.
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1063-1074. doi: 10.1007/s00259-021-05550-6. Epub 2021 Sep 6. PMID: 34486070; PMCID: PMC8803683.

277. Del Giudice F, Flammia RS, Chung BI, Moschini M, Pradere B, Mari A, Soria F, Albisinni S, Krajewski W, Szydełko T, Laukhtina E, D’Andrea D, Gallioli A, Mertens LS, Maggi M, Sciarra A, Salciccia S, Ferro M, Scornajenghi CM, Asero V, Cattarino S, De Angelis M, Cacciamani GE, Autorino R, Pandolfo SD, Falagario UG, D’Altilia N, Mancini V, Chirico M, Cinelli F, Bettocchi C, Cormio L, Carrieri G, De Berardinis E, Busetto GM, On Behalf Of European Association Of Urology Eau- Young Academic Urologists Yau Urothelial Cancer Working Party.
Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis.
Cancers (Basel). 2022 Feb 10;14(4):887. doi: 10.3390/cancers14040887. PMID: 35205635; PMCID: PMC8869903.

278. Del Giudice F, Belladelli F, Chen T, Glover F, Mulloy EA, Kasman AM, Sciarra A, Salciccia S, Canale V, Maggi M, Ferro M, Busetto GM, De Berardinis E, Salonia A, Eisenberg ML.
The association of impaired semen quality and pregnancy rates in assisted reproduction technology cycles: Systematic review and meta-analysis. 
Andrologia. 2022 Mar 3:e14409. doi: 10.1111/and.14409. Epub ahead of print. PMID: 35244232.

279. Ferro M, Chiujdea S, Musi G, Lucarelli G, Del Giudice F, Hurle R, Damiano R, Cantiello F, Mari A, Minervini A, Busetto GM, Carrieri G, Crocetto F, Barone B, Caputo VF, Cormio L, Ditonno P, Sciarra A, Terracciano D, Cioffi A, Luzzago S, Piccinelli M, Mistretta FA, Vartolomei MD, de Cobelli O.
Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis.
Clin Genitourin Cancer. 2021 Dec 10:S1558-7673(21)00234-2. doi: 10.1016/j.clgc.2021.12.005. Epub ahead of print. PMID: 35033480.

280. Del Giudice F, van Uem S, Li S, Vilson FL, Sciarra A, Salciccia S, Busetto GM, Maggi M, Tiberia L, Viscuso P, Canale V, Panebianco V, Pecoraro M, Ferro M, Moschini M, Krajewski W, D’Andrea D, Cacciamani GE, Mari A, Soria F, Porpiglia F, Fiori C, Amparore D, Checcucci E, Autorino R, De Berardinis E, Chung BI.
Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs.
Clin Genitourin Cancer. 2021 Dec 24:S1558-7673(21)00243-3. doi: 10.1016/j.clgc.2021.11.016. Epub ahead of print. PMID: 35031226.

281. Del Giudice F, Flammia RS, Pecoraro M, Moschini M, D’Andrea D, Messina E, Pisciotti LM, De Berardinis E, Sciarra A, Panebianco V.
The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations.
World J Urol. 2022 Mar 16. doi: 10.1007/s00345-022-03969-6. Epub ahead of print. PMID: 35294583.

282. Gacci M, Greco I, Artibani W, Bassi P, Bertoni F, Bracarda S, Briganti A, Carmignani G, Carmignani L, Conti GN, Corvò R, De Nunzio C, Fusco F, Graziotti P, Maggi S, Magrini SM, Mirone V, Montironi R, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Salonia A, Simonato A, Serni S, Tubaro A, Zagonel V, Crepaldi G; Pros-IT CNR Study Group.
The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study.
Minerva Urol Nephrol. 2022 Feb;74(1):38-48. doi: 10.23736/S2724-6051.20.03925-9. Epub 2020 Nov 17. PMID: 33200896.

283. Del Monte M, Cipollari S, Del Giudice F, Pecoraro M, Bicchetti M, Messina E, Dehghanpour A, Ciardi A, Sciarra A, Catalano C, Panebianco V.
MRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques.
Br J Radiol. 2022 Mar 1;95(1131):20210528. doi: 10.1259/bjr.20210528. Epub 2021 Oct 5. PMID: 34609900.

284. Palumbo C, Bruni A, Antonelli A, Artibani W, Bassi P, Bertoni F, Borghetti P, Bracarda S, Cicchetti A, Corvò R, Gacci M, Ingrosso G, Magrini SM, Maruzzo M, Mirone V, Montironi R, Muto G, Noale M, Porreca A, Russi E, Triggiani L, Tubaro A, Valdagni R, Maggi S, Conti GN; Pros-IT CNR Study Group.
Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study.
Minerva Urol Nephrol. 2022 Feb;74(1):11-20. doi: 10.23736/S2724-6051.20.04032-1. Epub 2021 Jan 13. PMID: 33439570.

285. Frisenda M, Signore S, Delicato G, Martinelli AG, Cantiani A, Colafelice M, Tufano A, Del Giudice F, Eisenberg ML, Sciarra A, Canale V.
Influence of COVID-19 pandemic on timing and outcomes of treatment for acute testicular torsion in adults: a single institution experience.
Can J Urol. 2022 Apr;29(2):11095-11100. PMID: 35429428.

286. Ferro M, Tătaru OS, Musi G, Lucarelli G, Abu Farhan AR, Cantiello F, Damiano R, Hurle R, Contieri R, Busetto GM, Carrieri G, Cormio L, Del Giudice F, Sciarra A, Perdonà S, Borghesi M, Terrone C, La Civita E, Bove P, Autorino R, Muto M, Crisan N, Marchioni M, Schips L, Soria F, Terracciano D, Papalia R, Crocetto F, Barone B, Russo GI, Luzzago S, Ludovico GM, Vartolomei MD, Mistretta FA, Mirone V, de Cobelli O.
Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy.
Diagnostics (Basel). 2022 Feb 25;12(3):586. doi: 10.3390/diagnostics12030586. PMID: 35328139; PMCID: PMC8947693.

287. Procopio G, Chiuri VE, Giordano M, Alitto AR, Maisano R, Bordonaro R, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico GM, Guglielmini PF, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D; ABItude Study Group.
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
ESMO Open. 2022 Apr 8;7(2):100431. doi: 10.1016/j.esmoop.2022.100431. Epub ahead of print. PMID: 35405438.

288. Di Lascio G, Sciarra A, Del Giudice F, Salciccia S, Busetto GM, De Berardinis E, Ricciuti GP, Castellani D, Pirola GM, Maggi M, Gentilucci A, Cattarino S, Mariotti G, Casale P, Di Pierro GP
Which factors can influence post-operative renal function preservation after nephron-sparing surgery for kidney cancer: a critical review
Central European journal Urol Issue:2022, Vol. 75, No. 1; 14-27 Published on-line:Jan 12, 2022; doi: 10.5173/ceju.2021.0256

289. Mariotti G, Sciarra A, Salciccia S, Cattarino S, Fiori C, Gentilucci A.
Quantitative analysis of urinary incontinence after prostatectomy: lack of standardization in trials
MINERVA UROLOGY AND NEPHROLOGY. – ISSN 2724-6051. – 74(3):(2022). [10.23736/S2724-6051.22.04958-8]

290. Salciccia S, Sciarra A, Cattarino S, Mariotti G, Bevilacqua G, Gentilucci A.
Comment on: Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis
MINERVA UROLOGY AND NEPHROLOGY. – ISSN 2724-6051. – 74(3):(2022). [10.23736/S2724-6051.22.04948-5]

291. Mariotti G, Salciccia S, Viscuso P, Bevilacqua G, Casale P, Frisenda M, Di Pierro GB, Cattarino S, Gentilucci A, Rosati D, Sciarra B, Sciarra A.
Regenerative medicine-based treatment of stress urinary incontinence with stem cells: a systematic review and meta-analysis.
Curr Stem Cell Res Ther. 2022 Jun doi: 10.2174/1574888X17666220616100621.

292. Salciccia S, Viscuso P, Bevilacqua G, Tufano A, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Gentilucci A, Lourdes Lia F, Di Giulio I, Rosati D, Del Giudice F, Sciarra A, Mariotti G.
Comparison of Different Invasive Devices for the Treatment of Urinary Incontinence after Radical Prostatectomy.
Advances in Urology 2022. Volume 2022, Article ID 8736249, https://doi.org/10.1155/2022/8736249

293. Lucciola S, Pisciotti ML, Frisenda M, Magliocca F, Gentilucci A, Del Giudice F, Canale V, Scarrone E, Busetto GM, Carrieri G, Cormio L, Carbone A, Pastore A, De Nunzio C, Tubaro A, Leonardo C, Franco G, Di Pierro GB, Salciccia S, Sciarra A, Panebianco V.
Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms.
Prostate Cancer Prostatic Dis. 2022 Jun 22. doi: 10.1038/s41391-022-00564-z. Epub ahead of print. PMID: 35732820.

294. Ornaghi PI, Porreca A, Sandri M, Sciarra A, Falsaperla M, Ludovico GM, Cerruto MA, Antonelli A.
Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases.
Prostate Cancer Prostatic Dis. 2022 Jul 22. doi: 10.1038/s41391-022-00575-w. Epub ahead of print. PMID: 35869394.

295. Salciccia S, Frisenda M, Bevilacqua G, Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Giorgino G, Rosati D, Del Giudice F, Sciarra A, Mariotti G, Gentilucci A.
Prognostic Value of Albumin to Globulin Ratio in Non-Metastatic and Metastatic Prostate Cancer Patients: A Meta-Analysis and Systematic Review.
Int J Mol Sci. 2022 Sep 29;23(19):11501. doi: 10.3390/ijms231911501. PMID: 36232828.

296. Al Salhi Y, Fuschi A, Martoccia A, DE Nunzio C, Bozzini G, Sciarra A, Maggi M, Illiano E, Costantini E, Asimakopoulos A, Carbone A, Pastore AL.
Impact of early self-clean intermittent catheterization in orthotopic ileal neobladder: prospective randomized study to evaluate functional outcomes, continence status and urinary tract infections.
Minerva Urol Nephrol. 2022 Oct 5. doi: 10.23736/S2724-6051.22.04944-8. Epub ahead of print. PMID: 36197699.

297. Tafuri A, Marchioni M, Cerrato C, Mari A, Tellini R, Odorizzi K, Veccia A, Amparore D, Shakir A, Carbonara U, Panunzio A, Trovato F, Catellani M, Janello LMI, Bianchi L, Novara G, Dal Moro F, Schiavina R, De Lorenzis E, Parma P, Cimino S, De Cobelli O, Maiorino F, Bove P, Crocerossa F, Cantiello F, D’Andrea D, Di Cosmo F, Porpiglia F, Ditonno P, Montanari E, Soria F,  Gontero P, Liguori G, Trombetta C, Mantica G, Borghesi M, Terrone C, Del Giudice F, Sciarra A, Galosi A, Moschini M, Shariat SF, Di Nicola M, Minervini A, Ferro M, Cerruto MA, Schips L, Pagliarulo V, Antonelli A.
Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium).
World J Urol. 2022 Oct 6. doi: 10.1007/s00345-022-04156-3. Epub ahead of print. PMID: 36203101.

298. Del Giudice F, Kim W, Li S, DE Berardinis E, Sciarra A, Salciccia S, Ferro M, Autorino R, Pandolfo SD, Crocetto F, Galfano A, Dell’oglio P, Cacciamani GE, Pradere B, Laukhtina E, D’Andrea D, Belladelli F, Krajewski W, Mari A, Minervini A, Gallioli A, Amparore D, Checcucci E, Fiori C, Porpiglia F, Morgantini L, Crivellaro S, Chung BI.
Management of the incidental adrenal mass, continued surveillance versus surgical excision: analysis of US claims data on contemporary socio-demographic predictors and peri-operative outcomes.
Minerva Urol Nephrol. 2022 Oct 5. doi: 10.23736/S2724-6051.22.05073-X. Epub ahead ofprint. PMID: 36197701.